![]() ![]() Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Follicular lymphoma: 2015 update on diagnosis and management. Allogeneic transplantation for follicular lymphoma: does one size fit all? J Oncol Pract. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, López-Guillermo A, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, et al. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, et al. Current perspectives on the treatment of double hit lymphoma. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Sarkozy C, Traverse-Glehen A, Coiffier B. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, et al. The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy. ![]() Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Vardhana SA, Sauter CS, Matasar MJ, Zelenetz AD, Galasso N, Woo KM, et al. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soc Hematol Educ Program. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. Van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Diffuse large B-cell lymphoma version 1.2016. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |